Libtayo Europska Unija - hrvatski - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karcinom, squamous cell - antineoplastična sredstva - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Cresemba Europska Unija - hrvatski - EMA (European Medicines Agency)

cresemba

basilea pharmaceutica deutschland gmbh - isavuconazole - aspergiloza - cresemba prikazan kod odraslih za liječenje:invazivne aspergillosismucormycosis kod pacijenata, za koje je amfotericin b inappropriateconsideration treba davati službene preporuke za odgovarajuće korištenje antifungalna lijekova.

MON.TEK⁹⁹Mo/⁹⁹ᵐTc GENERATOR 5 gigaBq/1 dan i sat kalibracije  50 gigaBq/1 dan i sat kalibracije radionuklidni generator Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

mon.tek⁹⁹mo/⁹⁹ᵐtc generator 5 gigabq/1 dan i sat kalibracije 50 gigabq/1 dan i sat kalibracije radionuklidni generator

intrade pharm d.o.o. sarajevo - tehnecijum (99mtc) pertehnetat - radionuklidni generator - 5 gigabq/1 dan i sat kalibracije 50 gigabq/1 dan i sat kalibracije - natrijummolibdat (mo99)….. 550 gbq (na dan kalibracije) natrijumpertehnetat (99mtc)…..gbq (u zavisnosti od aktivnosti mo99)

MON.IYOT131 0,37 megaBq/1 kapsula  7400 megaBq/1 kapsula kapsula, tvrda Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

mon.iyot131 0,37 megabq/1 kapsula 7400 megabq/1 kapsula kapsula, tvrda

intrade pharm d.o.o. sarajevo - natrijum jodid (131 i) - kapsula, tvrda - 0,37 megabq/1 kapsula 7400 megabq/1 kapsula - 1 kapsula, tvrda sadrži: 131 i kao natrijev jodid (131i) 0,377400 mbq (10 μci – 200 mci)

Foscan Europska Unija - hrvatski - EMA (European Medicines Agency)

foscan

biolitec pharma ltd - temoporfin - head and neck neoplasms; carcinoma, squamous cell - antineoplastična sredstva - foscan je naznačeno palijativnoj terapiji bolesnika s naprednim glave i vrata planocelularni karcinom neuspjeha prethodne terapije i neprikladan za radioterapiju, operacije ili sustavne kemoterapije.